

J1131
12/10/01

UTILITY PATENT
APPLICATION TRANSMITTAL
(Under 37 C.F.R. §1.53(b))

Docket No.: V-260.00

Page 1 of 2

Title: Improved Method For Large Scale Production of
Virus Antigen

Express Mail Label No.: (n/a)

Jc9710/006881 PTO

APPLICATION ELEMENTS

INVENTORS: Manfred Reiter
Wolfgang Mundt

ADDRESS TO: Assistant Commissioner for Patents

Box Patent Application
Washington, D.C. 20231

1. <input checked="" type="checkbox"/>	Fee Transmittal Form (Submit an original, and a duplicate for fee processing)	10. <input type="checkbox"/>	Information Disclosure Statement (IDS)/PTO-1449	<input type="checkbox"/> Copies of IDS Citations
2. <input checked="" type="checkbox"/>	Specification [Total Pages 23]	11. <input type="checkbox"/>	Preliminary Amendment	
3. <input type="checkbox"/>	Drawing(s) (35 USC §113) [Total Pages (Fig.)]	12. <input checked="" type="checkbox"/>	Return Receipt Postcard (MPEP 503)	
4. <input type="checkbox"/>	Signed Declaration [Total Pages]	13. <input type="checkbox"/>	Small Entity Statement(s)	
a. <input type="checkbox"/>	Newly executed (original or copy)	14. <input type="checkbox"/>	Certified Copy of Priority Documents (s)	
b. <input type="checkbox"/>	Copy from a prior application (37 CFR §1.63(d))	15a. <input type="checkbox"/>	Cancel in the application original claims _____ before calculating the filing fee	
(Note Box 5 below)				
i. <input type="checkbox"/>	<u>DELETION OF INVENTOR(S)</u>	15b. <input type="checkbox"/>	Amend the specification by inserting before the first line the sentence: --This is a <u> </u> Continuation, <u> </u> Divisional, <u> </u> Continuation-in-part, of application _____, filed _____.	
<p>Signed statement attached deleting invento named in the prior application, see 37 CFR §§1.63(d)(2) and 1.33(b)</p>				
5. <input type="checkbox"/>	Incorporation By Reference (useable if Box 4b is checked.) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.	15c. <input type="checkbox"/>	I hereby verify that the attached papers are a true copy of the latest inventor-signed prior application, including a copy of the oath or declaration showing the original signature or an indication it was signed. I hereby verify that the papers are a true copy of the latest signed prior application number _____, filed _____ aAnd further that all statements made herein of my own knowledge are true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any Patent issuing thereon.	
6. <input type="checkbox"/>	Nucleotide and/or Amino Acid Sequence Submission			
a. <input type="checkbox"/>	Computer Readable Copy			
b. <input type="checkbox"/>	Paper Copy (identical to computer copy)			
c. <input type="checkbox"/>	Statement Verifying identify of above copies			
7. <input type="checkbox"/>	Assignment Papers (cover sheet & document(s))	15d. <input type="checkbox"/>	Other: _____	
8. <input type="checkbox"/>	37 CFR §3.73(b) Statement	<input type="checkbox"/>	Power of Attorney	
9. <input type="checkbox"/>	English Translation Document	15e. <input type="checkbox"/>	Other _____	
16. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:				
<input type="checkbox"/>	Continuation	<input type="checkbox"/>	Divisional	<input type="checkbox"/>
			Continuation-in-part (CIP)	of prior application No.: _____

UTILITY PATENT
APPLICATION TRANSMITTAL
(Under 37 C.F.R. §1.53(b))

Docket No.: V-260.00
Title: Improved Method For Large Scale Production of
Virus Antigen
Express Mail Label No.: (n/a)

Page 2 of 2

CLAIMS	(1) FOR	(2) NUMBER	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(b))	38-20 =	18	X \$ 18 =	\$324.00
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	10-3 =	7	X \$ 84 =	\$588.00
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR §1.16(d))			+ \$ 280 =	\$ 0
				BASIC FEE (37 CFR §1.16(a))	\$740.00
				TOTAL =	\$1652.00

The Commissioner is hereby authorized to credit overpayments or charge the following fees, and any other fees necessary during the pendency of the application, to Deposit Account No. 02 -1437 (Docket V-260.00).
(For this purpose, pursuant to 37 CFR §1.136(a)(3) please incorporate the above authorization into any future reply as a petition for an appropriate extension of time if a petition for an extension of time is not otherwise provided.)

- a. Fees required under 37 CFR §1.16
- b. Fees required under 37 CFR §1.17
- c. Fees required under 37 CFR §1.18

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

NAME	C. Joseph Faraci, Reg. No. 32,350
SIGNATURE	
DATE	December 6, 2001

CORRESPONDENCE ADDRESS

Baxter Healthcare Corporation
P.O. Box 15210
Irvine, California 92614
Telephone: (949) 250-6827 Fax: (949) 474-6330

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.10

I hereby certify that the above identified document is being deposited with the United States Postal Service as Express Mail in an envelope, addressed to: Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231 on 12/06/2001.

By: